NO303645B1 - Testmetode for Õ identifisere en forbindelse som er i stand til Õ inhibere en herpes simplex (HSV) protease og anvendelse av et proteinsubstrat og anvendelse av inhibitor - Google Patents

Testmetode for Õ identifisere en forbindelse som er i stand til Õ inhibere en herpes simplex (HSV) protease og anvendelse av et proteinsubstrat og anvendelse av inhibitor Download PDF

Info

Publication number
NO303645B1
NO303645B1 NO922029A NO922029A NO303645B1 NO 303645 B1 NO303645 B1 NO 303645B1 NO 922029 A NO922029 A NO 922029A NO 922029 A NO922029 A NO 922029A NO 303645 B1 NO303645 B1 NO 303645B1
Authority
NO
Norway
Prior art keywords
protease
hsv
protein
herpes
plasmid
Prior art date
Application number
NO922029A
Other languages
English (en)
Norwegian (no)
Other versions
NO922029L (no
NO922029D0 (no
Inventor
Bernard Roizman
Fenyong Liu
Original Assignee
Arch Dev Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/832,855 external-priority patent/US5478727A/en
Application filed by Arch Dev Corp filed Critical Arch Dev Corp
Publication of NO922029D0 publication Critical patent/NO922029D0/no
Publication of NO922029L publication Critical patent/NO922029L/no
Publication of NO303645B1 publication Critical patent/NO303645B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
NO922029A 1991-05-24 1992-05-22 Testmetode for Õ identifisere en forbindelse som er i stand til Õ inhibere en herpes simplex (HSV) protease og anvendelse av et proteinsubstrat og anvendelse av inhibitor NO303645B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70581491A 1991-05-24 1991-05-24
US07/832,855 US5478727A (en) 1991-05-24 1992-02-07 Methods and compositions for the preparation and use of a herpes protease

Publications (3)

Publication Number Publication Date
NO922029D0 NO922029D0 (no) 1992-05-22
NO922029L NO922029L (no) 1992-11-25
NO303645B1 true NO303645B1 (no) 1998-08-10

Family

ID=27107575

Family Applications (1)

Application Number Title Priority Date Filing Date
NO922029A NO303645B1 (no) 1991-05-24 1992-05-22 Testmetode for Õ identifisere en forbindelse som er i stand til Õ inhibere en herpes simplex (HSV) protease og anvendelse av et proteinsubstrat og anvendelse av inhibitor

Country Status (13)

Country Link
EP (1) EP0514830B1 (fr)
JP (1) JP3355202B2 (fr)
AT (1) ATE192494T1 (fr)
AU (1) AU666305B2 (fr)
CA (1) CA2069460C (fr)
DE (2) DE69230984D1 (fr)
ES (1) ES2145742T3 (fr)
FI (1) FI104427B (fr)
HU (1) HU216622B (fr)
IE (1) IE921656A1 (fr)
IL (1) IL101975A (fr)
NO (1) NO303645B1 (fr)
NZ (1) NZ242739A (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406902B1 (en) 1991-07-05 2002-06-18 Johns Hopkins University Herpes virus proteinase and methods of assaying
US5434074A (en) * 1991-07-05 1995-07-18 Gibson; D. Wade Cytomegalovirus proteinase
US5376633A (en) * 1992-09-30 1994-12-27 Lezdey; John Method for deactivating viruses in blood component containers
JPH08510918A (ja) * 1993-06-08 1996-11-19 アボツト・ラボラトリーズ 単純ヘルペスウィルス２型プロテアーゼ
EP0714399A4 (fr) * 1993-08-20 1999-01-27 Smithkline Beecham Corp Gene hsv-2 ul26, proteines capsides, dosages immunologiques et inhibiteurs de protease
US5506115A (en) * 1994-04-29 1996-04-09 G. D. Searle & Co. Reagent and method for determining activity of herpes protease
US5945425A (en) * 1994-04-29 1999-08-31 G.D. Searle & Co. Method of using (H+ /K+)ATPase inhibitors as antiviral agents
US5486470A (en) * 1994-07-21 1996-01-23 Merck & Co., Inc. Purified herpes simplex virus protease and methods of purification
US5618685A (en) * 1995-04-06 1997-04-08 Merck & Co., Inc. Activation of herpes simplex virus protease by kosmotropes
US5985872A (en) * 1995-05-24 1999-11-16 G.D. Searle & Co. 2-amino-benzoxazinones for the treatment of viral infections
WO1996038546A1 (fr) * 1995-06-01 1996-12-05 Merck & Co., Inc. Mutants de la protease du virus de l'herpes simplex du type 1 et vecteurs associes
US6083711A (en) * 1996-05-15 2000-07-04 Smithkline Beecham Corporation Proteases compositions capable of binding to said site, and methods of use thereof
US6756207B1 (en) 1997-02-27 2004-06-29 Cellomics, Inc. System for cell-based screening
ATE225406T1 (de) * 1998-10-30 2002-10-15 Cellomics Inc Ein screeningsystem auf zellbasis
AU780116B2 (en) * 1999-12-23 2005-03-03 Board Of Regents, The University Of Texas System Inhibition of cellular proteases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3800233A1 (de) * 1988-01-07 1989-07-20 Hans Prof Dr Dr Wolf Methoden fuer die gentechnologische produktion einer rekombinanten, enzymatisch aktiven hiv spezifischen protease und der vorlaeufermolekuele der gruppenspezifischen antigene (gag) und der polymerase (pol) und verwendung dieser produkte in ansaetzen zur testung von hiv-protease spezifischen inhibitoren

Also Published As

Publication number Publication date
JP3355202B2 (ja) 2002-12-09
AU1711292A (en) 1992-11-26
NO922029L (no) 1992-11-25
DE69230984T4 (de) 2001-04-05
FI922271L (fi) 1992-11-25
ATE192494T1 (de) 2000-05-15
EP0514830B1 (fr) 2000-05-03
EP0514830A3 (en) 1993-06-09
NO922029D0 (no) 1992-05-22
HUT65494A (en) 1994-06-28
EP0514830A2 (fr) 1992-11-25
AU666305B2 (en) 1996-02-08
CA2069460C (fr) 2002-12-31
IE921656A1 (en) 1992-12-02
ES2145742T3 (es) 2000-07-16
HU216622B (hu) 1999-07-28
DE69230984D1 (de) 2000-06-08
FI922271A0 (fi) 1992-05-19
FI104427B (fi) 2000-01-31
HU9201723D0 (en) 1992-08-28
DE69230984T2 (de) 2000-11-02
JPH05336964A (ja) 1993-12-21
IL101975A (en) 1998-08-16
NZ242739A (en) 1994-12-22
CA2069460A1 (fr) 1992-11-25

Similar Documents

Publication Publication Date Title
Brideau et al. The Us9 gene product of pseudorabies virus, an alphaherpesvirus, is a phosphorylated, tail-anchored type II membrane protein
NO303645B1 (no) Testmetode for Õ identifisere en forbindelse som er i stand til Õ inhibere en herpes simplex (HSV) protease og anvendelse av et proteinsubstrat og anvendelse av inhibitor
Jovasevic et al. Proteolytic cleavage of VP1-2 is required for release of herpes simplex virus 1 DNA into the nucleus
US5478727A (en) Methods and compositions for the preparation and use of a herpes protease
Kinchington et al. Nuclear accumulation of IE62, the varicella-zoster virus (VZV) major transcriptional regulatory protein, is inhibited by phosphorylation mediated by the VZV open reading frame 66 protein kinase
Nixdorf et al. Effects of truncation of the carboxy terminus of pseudorabies virus glycoprotein B on infectivity
Mettenleiter et al. Mapping of the structural gene of pseudorabies virus glycoprotein A and identification of two non-glycosylated precursor polypeptides
IE83278B1 (en) Use of a herpes protease
Jones et al. Proteolytic activity of human cytomegalovirus UL80 protease cleavage site mutants
Person et al. Capsids are formed in a mutant virus blocked at the maturation site of the UL26 and UL26. 5 open reading frames of herpes simplex virus type 1 but are not formed in a null mutant of UL38 (VP19C)
Unal et al. The protease and the assembly protein of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8)
Oien et al. Assembly of herpes simplex virus capsids using the human cytomegalovirus scaffold protein: critical role of the C terminus
McMahon et al. Interactions between human cytomegalovirus helicase–primase proteins
Pasieka et al. A functional YNKI motif in the short cytoplasmic tail of varicella-zoster virus glycoprotein gH mediates clathrin-dependent and antibody-independent endocytosis
Marsden et al. The herpes simplex virus type 1 UL8 protein influences the intracellular localization of the UL52 but not the ICP8 or POL replication proteins in virus-infected cells
EP0769056B1 (fr) VARIANTES NON EPISSABLES DES gp 350 ET 220
LaFemina et al. Characterization of a soluble stable human cytomegalovirus protease and inhibition by M-site peptide mimics
Loveland et al. Cleavage of human cytomegalovirus protease pUL80a at internal and cryptic sites is not essential but enhances infectivity
Huang et al. Characterization and expression of the pseudorabies virus early gene UL54
Chan et al. Cytomegalovirus assemblin (pUL80a): cleavage at internal site not essential for virus growth; proteinase absent from virions
Yang et al. Proline and tyrosine residues in scaffold proteins of herpes simplex virus 1 critical to the interaction with portal protein and its incorporation into capsids
Robertson et al. Na, an autoproteolytic product of the herpes simplex virus type 1 protease, can functionally substitute for the assembly protein ICP35
US6692749B1 (en) Non-splicing variants of gp350/220
Gray et al. Simian varicella virus gene 61 encodes a viral transactivator but is non-essential for in vitro replication
Ko et al. Analysis of IE62 mutations found in Varicella-Zoster virus vaccine strains for transactivation activity